Navigation Links
Attorney Weight Loss Video to be Released by Leventhal Weight Loss Incorporated
Date:4/7/2008

se a customized and individualized plan

tailored to each attorneys strengths and particular lifestyle;

-- We provide advice, suggestions, hints, and ideas to ensure that

attorneys lose weight;

-- We also provide the support, motivation, and personal accountability;

-- The accountability and support can be daily. It can be weekly. It can

be whenever. We do what works for each and every attorney; and

-- We have a 100% success rate among clients who are committed to losing

weight.

Mr. Leventhal himself lost over 50 pounds while practicing international trade law in a Washington, D.C. law firm, and has since run and completed nine marathons. He understands what it is like to be overweight and practicing law. He understands, too, the importance of convenience to attorneys and will consult with them at their convenience -- even at 2 AM, when they may be driving home from work, or just wrapping up that brief. Mr. Leventhal has been featured in, among other publications, the ABA Journal, The Wall Street Journal Law Blog, the Washington Post, the Washington Post Express, and the Young Lawyer, a publication of The Legal Intelligencer. His healthier lifestyle presentations have been well received by law firms such as Holland & Knight LLP and bar associations such as The Bar Association of Frederick County, Maryland, Inc.

For more information visit http://www.attorneyweightloss.com or contact Mark Leventhal, Esq., at 202-550-8638 and at mark@attorneyweightloss.com.


'/>"/>
SOURCE Leventhal Weight Loss Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Bikini Model to be Featured in Attorney Weight Loss Video
2. Leventhal Weight Loss Incorporated Becomes First in the Nation Executive Weight Loss Consulting Service for Attorneys by an Attorney
3. Attorney General Corbett Announces $36.7 Million Multi-State Settlement With CVS/Caremark in National Dosage-Switching Investigation
4. Cardinal Health Names Former Acting Deputy U.S. Attorney General Craig S. Morford to Chief Compliance Officer Post
5. Empire Blue Cross Blue Shield Statement in Response to New York Attorney Generals Recent Subpoenas
6. TransUnion Addresses Ohio Attorney Generals Concerns Surrounding Non-Profit Tax-Exempt Status
7. Anapol Schwartz Attorney Representing Trasylol(R) Victims Says Medical Study - Confirming Heart Bypass Drug Mortality Risk - to Open Floodgates for More Litigation
8. Pennsylvania Attorney General Corbett Announces Multi-State Settlement With Caremark
9. AHIP Statement on New York Attorney Generals Announcement
10. Pennsylvania Attorney General Approves Vincentian Collaborative System-Marian Manor Integration
11. Former FTC Attorney Christine White Joins Crowell & Morings Health Care and Antitrust Groups
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10Lethality of H1N1 Influenza Virus Increasing According to Latest Replikin Analysis of Virus Peptide Genomic Data 48682 1Lethality of H1N1 Influenza Virus Increasing According to Latest Replikin Analysis of Virus Peptide Genomic Data 48682 2Lethality of H1N1 Influenza Virus Increasing According to Latest Replikin Analysis of Virus Peptide Genomic Data 48682 3AMA Cheers Senate Passage of Historic Tobacco Regulation Bill 48678 1AMA Cheers Senate Passage of Historic Tobacco Regulation Bill 48678 2Anderson ED Team Receives Pinnacle Award for Excellence in Customer Service 48674 1Anderson ED Team Receives Pinnacle Award for Excellence in Customer Service 48674 2Anderson ED Team Receives Pinnacle Award for Excellence in Customer Service 48674 3
Other Medicine Technology:Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 2Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 3Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 4Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 5Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 6Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 7Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 8In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 2In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 3In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 4In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 5In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 6In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 7In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 8In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 9